Get the Stockscreener App
0.275
20.36%
-0.0703
After Hours:
.28
0.005
+1.82%
Kala Bio Inc stock is traded at $0.275, with a volume of 2.96M.
It is down -20.36% in the last 24 hours and down -31.08% over the past month.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
See More
Previous Close:
$0.3453
Open:
$0.3542
24h Volume:
2.96M
Relative Volume:
0.43
Market Cap:
$250.62M
Revenue:
$5.75M
Net Income/Loss:
$-38.96M
P/E Ratio:
-0.0221
EPS:
-12.47
Net Cash Flow:
$-32.63M
1W Performance:
-27.63%
1M Performance:
-31.08%
6M Performance:
-98.11%
1Y Performance:
-96.37%
1-Day Range:
$0.27
$0.3544
1-Week Range:
$0.27
$0.403
52-Week Range:
$0.27
$20.60
Kala Bio Inc Stock (KALA) Company Profile
Name
Kala Bio Inc
Sector
Industry
Phone
781-996-5252
Address
1167 MASSACHUSETTS AVENUE, ARLINGTON, MA
Compare KALA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KALA
Kala Bio Inc
|
0.275 | 314.68M | 5.75M | -38.96M | -32.63M | -12.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Kala Bio Inc Stock (KALA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-30-25 | Downgrade | Mizuho | Outperform → Neutral |
| Sep-29-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-29-25 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Sep-08-25 | Initiated | Mizuho | Outperform |
| Jul-11-25 | Initiated | Ladenburg Thalmann | Buy |
| Mar-30-22 | Downgrade | JP Morgan | Neutral → Underweight |
| Aug-06-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-14-20 | Downgrade | Jefferies | Buy → Hold |
| Jul-23-20 | Initiated | Northland Capital | Outperform |
| Jun-01-20 | Resumed | Oppenheimer | Outperform |
| May-27-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-09-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Dec-17-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Mar-14-19 | Initiated | Jefferies | Buy |
View All
Kala Bio Inc Stock (KALA) Latest News
$167 Billion Invested in Biotech R&D is Underserved by AI, Offering Huge Opportunity for New On-Premises AI Infrastructure Platform from KALA BIO, Inc. (Nasdaq: KALA) - StreetInsider
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
KALA Unveils AI Platform to Revolutionize Biotech Data Managemen - GuruFocus
KALA Bio launches on-premises AI platform for biotech sector By Investing.com - Investing.com Australia
What's Going On With KALA BIO Stock Wednesday?Kala Bio (NASDAQ:KALA) - Benzinga
KALA Bio launches on-premises AI platform for biotech sector - Investing.com Nigeria
Kala Bio, Inc Announces Exclusive License Agreement with Younet Ai for Proprietary Ai Research Platform - marketscreener.com
Kala Bio Launches AI Platform for Biotech Industry - Data Center Knowledge
KALA BIO Secures Exclusive Researgency AI Platform License - TipRanks
KALA BIO (NASDAQ: KALA) signs exclusive Researgency AI license and $55M Younet option - Stock Titan
KALA Surges 14% on AI Licensing Strategy - GuruFocus
Kala Bio rises on plans to leverage AI (KALA:NASDAQ) - Seeking Alpha
KALA BIO Announces Strategic Initiative to Deploy and - GlobeNewswire
KALA BIO, Inc. (NASDAQ:KALA) Given Average Rating of "Hold" by Analysts - MarketBeat
KALA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Kala Bio (KALA) Stock Analysis Report | Financials & Insights - Benzinga Japan
Brendan P. Purdy Net Worth (2026) - GuruFocus
Hillel D. Posen Net Worth (2026) - GuruFocus
Comparing KALA BIO (NASDAQ:KALA) and Adagene (NASDAQ:ADAG) - Defense World
David Lazar resigns from KALA BIO board - TradingView
Why KALA BIO Inc. stock could benefit from AI revolutionQuarterly Portfolio Report & Smart Allocation Stock Tips - mfd.ru
Can KALA BIO Inc. withstand a market correction2025 Major Catalysts & Advanced Technical Analysis Signals - mfd.ru
Director David Lazar resigns from KALA BIO (NASDAQ: KALA) board - Stock Titan
Baker Bros. discloses 9.99% KALA BIO (KALA) stake via convertible preferred - Stock Titan
MSN Money - MSN
KALA.O PE Ratio & Valuation, Is KALA.O Overvalued - Intellectia AI
KALA Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Can KALA BIO Inc. outperform under higher oil pricesRecession Risk & Weekly Hot Stock Watchlists - mfd.ru
Can KALA BIO Inc. be the next market leader2025 Winners & Losers & AI Powered Trade Plan Recommendations - mfd.ru
Market Catalysts: Is KALA BIO Inc part of any major indexQuarterly Performance Summary & Reliable Price Breakout Alerts - baoquankhu1.vn
KALA to Offer 241.44 Million Shares in New Stock Sale - GuruFocus
Macro Review: Can KALA BIO Inc stock outperform in a bear market2025 Buyback Activity & Reliable Price Action Trade Plans - baoquankhu1.vn
KALA BIO (KALA) names director Avi Minkowitz CEO and CFO as David Lazar steps down - Stock Titan
Bearish Setup: Can Arm Holdings plc Depositary Receipt outperform under higher oil pricesRate Hike & Scalable Portfolio Growth Methods - baoquankhu1.vn
KALA BIO expands preferred financing and shareholder authorizations - The Globe and Mail
KALA BIO Signs Securities Purchase Agreement With Series AAA Investors - TradingView
KALA: All proposals, including director elections and share increases, passed with no stockholder questions - TradingView
KALA: All proposals, including director elections and share increase, passed unanimously - TradingView
KALA BIO Receives Nasdaq Notice on Listing Compliance - The Globe and Mail
KALA Bio Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Aug EndMonth: Is Codere Online Luxembourg SAs ROIC above industry averagePortfolio Performance Summary & Daily Stock Trend Watchlist - baoquankhu1.vn
Trading Action: Can LOAN weather a recessionTrade Risk Report & Low Risk Entry Point Tips - baoquankhu1.vn
KALA Stock Price, Forecast & Analysis | KALA BIO INC (NASDAQ:KALA) - Chartmill
Can KALA BIO Inc stock outperform in a bear marketWeekly Profit Analysis & Breakout Confirmation Trade Signals - baoquankhu1.vn
Why KALA BIO Inc stock is a must watch in 2025July 2025 PostEarnings & Community Driven Trade Alerts - Bộ Nội Vụ
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Kala Bio Stock Sinks On CEO Exit, But Retail Feels It’s An Overreaction - MSN
KALA BIO Inc. (KALA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
KALA BIO Launches At-the-Market Equity Offering Program - TipRanks
Why hedge funds are buying KALA BIO Inc. stockPortfolio Growth Summary & Risk Adjusted Swing Trade Ideas - Улправда
Can KALA BIO Inc. stock weather global recessionJuly 2025 Final Week & Real-Time Chart Breakout Alerts - Улправда
Kala Bio Inc Stock (KALA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Kala Bio Inc Stock (KALA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Reumuth Mary | CHIEF FINANCIAL OFFICER |
Oct 22 '25 |
Sale |
0.83 |
32,230 |
26,751 |
29,873 |
| Reumuth Mary | CHIEF FINANCIAL OFFICER |
Oct 23 '25 |
Sale |
0.82 |
967 |
793 |
28,906 |
| Bazemore Todd | Director |
Oct 22 '25 |
Sale |
0.83 |
47,768 |
39,647 |
35,932 |
| Brazzell Romulus K | SEE REMARKS |
Oct 22 '25 |
Sale |
0.83 |
46,748 |
38,801 |
35,952 |
| Kharabi Darius | CHIEF BUSINESS OFFICER |
Oct 22 '25 |
Sale |
0.83 |
20,806 |
17,269 |
41,760 |
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):